


Direct Entry to 4,10-Didesmethyl (9S)-Dihydroerythronolide A via Catalytic Allene Osmylation

Libing Yu,[†] Huan Wang,[†] Novruz G. Akhmedov,[‡] Christopher Sowa,[†] Kai Liu,[†] Hiyun Kim,[†] and Lawrence Williams^{*,†}[†]Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States[‡]Department of Chemistry, West Virginia University, 406 Clark Hall, Prospect Street, Morgantown, West Virginia 26506, United States

S Supporting Information

ABSTRACT: Desmethyl erythronolides have emerged as macrolide targets that may prove effective against resistant bacteria. A five-step sequence to 4,10-didesmethyl (9S)-dihydroerythronolide A (**1**) from known cyclic bis[allene] **13** is reported. Key structural and mechanistic aspects of the synthesis are discussed along with catalytic allene osmylation. An improved route to **13** is also described.



Pathogenic bacteria resistant to standard and last-resort therapies have prompted an intense search for novel antibiotics.¹ The complex macrolide erythromycin A (Figure 1)




Figure 1. Erythromycin A, (9S)-dihydroerythronolide A, **1**.

and its analogues have been used widely as first-line antibacterial agents.² However, resistance mechanisms in growing populations compromise their effectiveness. For example, the ribosomal A2058G mutation appears to render this binding site incompatible with the methyl substitution pattern of the macrolide.³ In principle, semisynthesis, total synthesis, and bioengineering methods would enable removal of certain combinations of methyl groups, but the task is not trivial. The complexity of erythromycin A limits direct access to these and related targets. The pressing importance of this problem prompted Andrade et al., in a tour de force, to evaluate desmethyl combinations through total syntheses.⁴ These highly refined syntheses required more than 25 linear steps each. We have demonstrated the benefits of an alternative strategy that uses an advanced, structurally complex macrocyclic bis[allene] to generate diverse 14-membered polyketides. In one to three steps we have been able to gain entry to diverse erythromycin A-related targets from this intermediate.⁵ This approach


deliberately incorporates sites of unsaturation into the scaffold for late-stage oxidation and diversification. Although our strategy deviates from some notions of synthetic ideality,⁶ it offers a much-improved cumulative step economy. In this report we demonstrate the superiority of this strategy with a concise synthesis of **1**, the 4,10-didesmethyl variant of (9S)-dihydroerythronolide A: compound **1** is prepared in five steps from **13**, our advanced intermediate, and in 16 linear steps overall; **13** is prepared by an improved and convenient route; a new procedure for catalytic osmium tetroxide oxidation of allenes is also described.

Schemes 1 and 2 summarize the synthesis of **1**. In our first-generation synthesis^{5b} certain intermediates proved either reluctant to react or sensitive to storage. Accordingly, intermediates 3–8 were modified, and the sequence was improved for operational convenience and scale and to ensure that key compounds could be readily stockpiled. As before, we lactonized prior to allene elaboration, since macrolide cyclization efficiency is notoriously sensitive to the functionality and stereochemistry of the seco acid. We eliminated the use of dimethoxy acetaldehyde as an aldol partner and adopted the use of acrolin, to which the chiral anion of **2** added smoothly, as reported.⁷ The resultant alcohol was readily masked as the benzyl ether (**3** → **4**).⁸ Hydride reduction provided primary alcohol **5**, which was converted to the corresponding tosylate and then displaced with acetylide (→ **7**). Aldehyde **6** was prepared from the antipode of **4** (*ent*-**4**) using Lemieux–Johnson conditions.^{9,10} Zinc bromide mediated addition of alkyne **7** to aldehyde **6**, as before,^{5b} afforded alkyne **8** with concomitant lactonization.¹¹ Oxidative cleavage of the terminal

Received: April 20, 2016

Published: June 7, 2016

Scheme 1. Synthesis of 13




alkene revealed aldehyde **9**,¹² which was joined with **10** and advanced to **13** as reported.


A five-step sequence from **13** to **1** is shown in Scheme 2a along with catalytic osmylation studies in Scheme 3 and Table 1. Owing to the need to effect divergent stereochemical outcomes for the hydroxyls at C5 and C11 (*vide infra*), we used a two-stage oxidation procedure. Treatment of **13** with osmium tetroxide gave hydroxy ketone **14** in excellent yield, regioselectivity, and stereoselectivity. Reduction with sodium borohydride afforded diol **15** (dr = 6:1). Catalytic osmylation of **15** was also highly efficient and selective. Reduction of the resultant ketone with zinc borohydride provided tetraol **16** (dr = 8:1), and hydrogenolysis cleanly furnished didesmethyl target **1**.

Lactonization, osmylation, and reduction of the C5 and C11 keto functionalities were examined in detail.¹³ The landmark total synthesis of erythromycin¹⁴ showed that successful macrolactonization of this target can be problematic. Cyclic motifs spanning C3–C5 and C9–C11 as well as the *S* configuration of the C9 combine to enable lactonization (Figure 1). These design principles have been followed in virtually all syntheses of the erythronolides.¹⁵ Although we opted to prepare the 9*S* configuration of **12**, we could not be certain that this feature and the allenic moieties spanning C4–C6 and C10–C12 would facilitate cyclization. In the event, **12** readily cyclized (Scheme 1). Still, we doubted that the configuration at C9 was essential for the success of this strategy and were anxious to test this hypothesis. Compound **20**, the C9 epimer of **12**, was prepared from **13** (Scheme 2b).

Scheme 2. Synthesis of 1 and Cyclization of 20




Scheme 3. Proposed Catalytic Cycle



The action of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) on **13** selectively cleaved the C9 benzyl ether in 60% yield.¹⁶ Mitsunobu conditions¹⁷ were successfully applied to afford, subsequent to methanolysis, **18**. After the matter of benzyl group reinstallation, lactone **19** was opened to give **20**, the 9*R* variant of **12**, and was then smoothly closed again (**20** → **21**). Although the somewhat stringent conditions required to open **19** also promoted epimerization at C2 (dr = 2:1),¹⁸ the mixture was taken on and efficiently cyclized in 70% overall yield (dr = 2:1).¹⁹ Indeed, this strategy is compatible with either configuration at C9.

Efficient catalytic allene oxidation with osmium tetroxide transforms each allenic moiety of substrate **13** to the corresponding hydroxy ketone with no evidence of regioisomeric or stereoisomeric products (Table 1). Excess osmium tetroxide (2.5 equiv) gave bicycle **22** (Table 1, entry 1). Inclusion of a tertiary amine greatly accelerated the reaction and gave **23** as the major product (Table 1, entry 2). DABCO

Table 1. Osmylation of Cyclic Bis[allene] 13



entry ^a	OsO ₄ (equiv)	additive (equiv)	time (h)	yield (%)		
				14	22	23
1	2.5	none	4	0	46	0
2	2.5	DABCO (4)	20 min	0	20	44
3	0.3	DABCO (4)	40 min	0	20	60
4	0.1	DABCO (4)	2	0	15	60
5	0.1	DABCO (1)	2	0	15	77
6	0.02	DABCO (0.2)	20	0	15	75

^aReaction conditions: 0.02–0.04 mmol of 13 in 1:1 *t*-BuOH/H₂O (0.03 M), rt; under catalytic conditions (Table 1, entries 3–6): *N*-methylmorpholine-*N*-oxide (2 equiv) was used as terminal oxidant. Yields were determined after FCC purification. DABCO = 1,4-diazabicyclo[2.2.2]octane.


outperformed pyridine and quinuclidine in terms of both yield and rate enhancement.²⁰ Catalysis was achieved using *N*-methylmorpholine-*N*-oxide (NMO) as terminal oxidant (Table 1, entries 3–6). In Table 1, entry 6 demonstrates that these conditions support low catalyst loading (2 mol %) for overnight reactions with virtually no change in yield.

Allene oxidation with osmium tetroxide proceeds by way of the osmium(VI) enolate²¹ (e.g., 13 → 24). Scheme 3 outlines a mechanistic framework for the conversion of 13 to 23. The osmium reagent approaches the most nucleophilic double bond (C5–C6) of 13 from the most accessible face to generate the *E*-enolate 24, which hydrolyzes to give 14. Similarly, 25 forms from approach of the oxidant to the most accessible face of the more substituted double bond (C11–C12) of the remaining allene to give the *E*-enolate. In our earlier work,^{5b} stoichiometric osmylation of the C10–C12 allene was confounded by an unwanted elimination/addition sequence that gave 22 instead of the desired 23. We posit that the persistent problem faced in previous allene osmylation reactions was the slow hydrolysis of the osmate ester and that DABCO, and other additives, accelerate this hydrolysis. In the present case, the ligand releases the macrocyclic diol from the osmium before this unwanted transformation can dominate. On the basis of these data, we conclude that the formation of 25 is effected by way of the osmium enolate or a close variant.

Catalytic allene oxidation enabled a two-step maneuver from allenic substrate 13 to macrocyclic diol analogues 27 and 28 (Scheme 4). Zinc borohydride reduction of 23 yielded 5 β ,11 β -tetraol 27, whereas sodium borohydride reduction yielded 5 α ,11 α -tetraol 28. These conditions furnished the products in excellent overall yield and complement the synthesis of 5 α ,11 β -target 1.²²

We have reported a series of allene oxidation/elaboration methods in both simplified and complex settings.²³ Catalytic methods to effect allene oxidation are underexplored and hold considerable promise for concise, practical, and broadly useful routes to high-value molecular architectures.²⁴ The present disclosure describes an improved route to 13, its subsequent conversion—in five or fewer steps—to erythronolides 1, 27, and 28, and catalytic oxidation of the allenic moieties with

Scheme 4. Two-Step Synthesis of Macrolides from 13



osmium tetroxide that made direct access to these targets possible.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.6b01151.

Procedures and additional data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: lwilliams@chem.rutgers.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We gratefully acknowledge financial support from the NIH (GM078145).

■ REFERENCES

- (a) Fishbach, M. A.; Walsh, C. T. *Science* **2009**, 325, 1089. (b) Walsh, C. T. *Nat. Rev. Microbiol.* **2003**, 1, 65. (c) Wright, G. D. *Chem. Commun.* **2011**, 47, 4055. (d) Wright, G. D. *Nat. Rev. Microbiol.* **2007**, 5, 175–186.
- (a) Katz, L.; Ashley, G. W. *Chem. Rev.* **2005**, 105, 499. (b) Pal, S. *Tetrahedron* **2006**, 62, 3171.
- (a) Bulkley, D.; Innis, C. A.; Blaha, G.; Steitz, T. A. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, 107, 17158. (b) Dunkle, J. A.; Xiong, L.; Mankin, A. S.; Cate, J. H. D. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, 107, 17152. (c) Tu, D.; Blaha, G.; Moore, P. B.; Steitz, T. A. *Cell* **2005**, 121, 257. (d) Hansen, J. L.; Ippolito, J. A.; Ban, N.; Nissen, P.; Moore, P. B.; Steitz, T. A. *Mol. Cell* **2002**, 10, 117. (e) Schlunzen, F.; Zarivach, R.; Harms, J.; Bashan, A.; Tocilj, A.; Albrecht, R.; Yonath, A.; Franceschi, F. *Nature* **2001**, 413, 814.
- (a) Velvadapu, V.; Paul, T.; Wagh, B.; Klepacki, D.; Guvench, O.; MacKerell, A., Jr; Andrade, R. B. *ACS Med. Chem. Lett.* **2011**, 2, 68. (b) Velvadapu, V.; Paul, T.; Wagh, B.; Glassford, I.; DeBrosse, C.; Andrade, R. B. *J. Org. Chem.* **2011**, 76, 7516. (c) Velvadapu, V.; Lee, M.; Paul, T.; DeBrosse, C.; Klepacki, D.; Small, M. C.; MacKerell, A. D., Jr; Andrade, R. B. *ACS Med. Chem. Lett.* **2012**, 3, 211. (d) Wagh, B.; Paul, T.; Glassford, I.; DeBrosse, C.; Klepacki, D.; Small, M. C.; MacKerell, A. D., Jr; Andrade, R. B. *ACS Med. Chem. Lett.* **2012**, 3, 1013. (e) Glassford, I.; Lee, M.; Wagh, B.; Velvadapu, V.; Paul, T.; Sandelin, G.; DeBrosse, C.; Klepacki, D.; Small, M.; MacKerell, A.; Andrade, R. B. *ACS Med. Chem. Lett.* **2014**, 5, 1021. (f) Andrade, R. B. *Synlett* **2015**, 26, 2199.
- (a) Ghosh, P.; Zhang, Y.; Emge, T. J.; Williams, L. J. *Org. Lett.* **2009**, 11, 4402. (b) Liu, K.; Kim, H.; Ghosh, P.; Akhmedov, N. G.; Williams, L. J. *J. Am. Chem. Soc.* **2011**, 133, 14968.
- (a) Gaich, T.; Baran, P. S. *J. Org. Chem.* **2010**, 75, 4657. (b) Hendrickson, J. B. *J. Am. Chem. Soc.* **1971**, 93, 6847.

(7) (a) Evans, D. A.; Bartroli, J.; Shih, T. L. *J. Am. Chem. Soc.* **1981**, *103*, 2127. (b) Nicolaou, K. C.; Brenzovich, W.; Bulger, P.; Francis, T. *Org. Biomol. Chem.* **2006**, *4*, 2119.

(8) The first-generation synthesis used dimethoxy acetaldehyde in the aldol addition reaction and required 2 days to convert the alcohol to the benzyl ether under more forcing conditions (3 equiv of Ag₂O and 2 equiv of BnBr).

(9) (a) Hua, Z.; Yu, W.; Jin, Z. *Org. Lett.* **2004**, *6*, 3217. (b) Because the α -position of aldehyde **6** epimerizes during silica gel chromatography, the crude material was used for the subsequent coupling reaction without purification.

(10) The use of the alkene avoids the problematic dimethyl acetal of the first-generation synthesis, which slowly hydrolyzed and decomposed upon storage.

(11) Mead, K. T. *Tetrahedron Lett.* **1987**, *28*, 1019.

(12) This procedure was more expeditious than the earlier synthesis (ref **5b**), which generated the aldehyde through acetic acid/TFA/water (4:1:1) cleavage of the corresponding acetal over the course of 14 h at rt. Acetic acid and water were insufficient.

(13) Glycosylation, which is essential for erythronolide bioactivity, will be discussed elsewhere.

(14) Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Au-Yeung, B.-W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H.; Chenevert, R. B.; Fliri, A.; Frobel, K.; Gais, H.-J.; Garratt, D. G.; Hayakawa, K.; Heggie, W.; Hesson, D. P.; Hoppe, D.; Hoppe, I.; Hyatt, J. A.; Ikeda, D.; Jacobi, P. A.; Kim, K. S.; Kobuke, Y.; Kojima, K.; Krowicki, K.; Lee, V. J.; Leutert, T.; Malchenko, S.; Martens, J.; Matthews, R. S.; Ong, B. S.; Press, J. B.; Rajan Babu, T. V.; Rousseau, G.; Sauter, H. M.; Suzuki, M.; Tatsuta, K.; Tolbert, L. M.; Truesdale, E. A.; Uchida, I.; Ueda, Y.; Uyehara, T.; Vasella, A. T.; Vladuchick, W. C.; Wade, P. A.; Williams, R. M.; Wong, H. N.-C. *J. Am. Chem. Soc.* **1981**, *103*, 3210, 3213, 3215.

(15) For cyclization with cyclic protecting groups spanning C3–C5 and C9–C11 as well as the S configuration at C9: (a) Stork, G.; Rychnovsky, S. D. *J. Am. Chem. Soc.* **1987**, *109*, 1565. (b) Nakata, M.; Arai, M.; Tomooka, K.; Ohsawa, N.; Kinoshita, M. *Bull. Chem. Soc. Jpn.* **1989**, *62*, 2618. (c) Hikota, M.; Tone, H.; Horita, K.; Yonemitsu, O. *J. Org. Chem.* **1990**, *55*, 7. (d) Myles, D. C.; Danishefsky, S. J.; Schulte, G. J. *Org. Chem.* **1990**, *55*, 1636. (e) Sviridov, A. F.; Borodkin, V. S.; Ermolenko, M. S.; Yashunsky, D. V.; Kochetkov, N. K. *Tetrahedron* **1991**, *47*, 2317. (f) Stürmer, R.; Ritter, K.; Hoffmann, R. W. *Angew. Chem., Int. Ed. Engl.* **1993**, *32*, 101. (g) Evans, D. A.; Kim, A. S.; Metternich, R.; Novack, V. J. *J. Am. Chem. Soc.* **1998**, *120*, 5921. (h) Peng, Z. H.; Woerpel, K. *J. Am. Chem. Soc.* **2003**, *125*, 6018. (i) Stang, E. M.; White, M. C. *Nat. Chem.* **2009**, *1*, 547. (j) Chandra, B.; Fu, D.; Nelson, S. G. *Angew. Chem., Int. Ed.* **2010**, *49*, 2591. For cyclization with a cyclic protecting group spanning C3–C5 and the S configuration at C9: (k) Corey, E. J.; Hopkins, P. B.; Kim, S.; Yoo, S. E.; Nambiar, K. P.; Falck, J. R. *J. Am. Chem. Soc.* **1979**, *101*, 7131. For cyclization without cyclic protecting group and with the S configuration at C9: (l) Paterson, I.; Rawson, D. J. *Tetrahedron Lett.* **1989**, *30*, 7463.

(16) This interesting selectivity may reflect the increased accessibility of the C-9 benzyl compared to the C-3 benzyl.

(17) Mitsunobu, O.; Yamada, Y. *Bull. Chem. Soc. Jpn.* **1967**, *40*, 2380.

(18) The macrolactone **19** resisted various hydrolysis conditions (e.g., LiOOH, 5 M KOH in H₂O/MeOH). Nevertheless concentrated sodium methoxide was found to open the macrolactone. The seco acid **20** was obtained as a mixture of inseparable C2 epimers (dr = 2:1). This finding is reminiscent of the findings of Martin et al., where the hydrolysis of a 14-membered lactone derived from erythromycin B proved stubbornly resistant to cleavage under a wide variety of reaction conditions. Martin, S. F.; Yamashita, M. *J. Am. Chem. Soc.* **1991**, *113*, 5478.

(19) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989.

(20) See [Supporting Information](#) for more details, including effects of HOAc and buffer.

(21) To our knowledge, this functionality has not been explored outside our laboratory.

(22) The structure of new compounds were assigned unambiguously by extensive NMR analysis; see the [Supporting Information](#).

(23) (a) Joyasawal, S.; Lotesta, S. D.; Akhmedov, N. G.; Williams, L. *J. Org. Lett.* **2010**, *12*, 988. (b) Ghosh, P.; Cusick, J. R.; Inghrim, J.; Williams, L. *J. Org. Lett.* **2009**, *11*, 4672. (c) Zhang, Y.; Cusick, J. R.; Ghosh, P.; Shangguan, N.; Katukojvala, S.; Inghrim, J.; Emge, T. J.; Williams, L. *J. Org. Chem.* **2009**, *74*, 7707. (d) Wang, Z.; Shangguan, N.; Cusick, J. R.; Williams, L. *Synlett* **2008**, *2008*, 213. (e) Lotesta, S. D.; Kiren, S.; Sauers, R. R.; Williams, L. *J. Angew. Chem., Int. Ed.* **2007**, *46*, 7108. (f) Ghosh, P.; Lotesta, S. D.; Williams, L. *J. Am. Chem. Soc.* **2007**, *129*, 2438. (g) Lotesta, S. D.; Hou, Y.; Williams, L. *J. Org. Lett.* **2007**, *9*, 869. (h) Katukojvala, S.; Barlett, K. N.; Lotesta, S. D.; Williams, L. *J. Am. Chem. Soc.* **2004**, *126*, 15348.

(24) Other than ref **5b**, allene oxidation with osmium tetroxide has been only tentatively examined: (a) Fleming, S. A.; Liu, R.; Redd, J. T. *Tetrahedron Lett.* **2005**, *46*, 8095. (b) Fleming, S. A.; Carroll, S. M.; Hirschi, J.; Liu, R.; Pace, J. L.; Redd, J. T. *Tetrahedron Lett.* **2004**, *45*, 3341. (c) Mereyala, H. B.; Gurrall, S. R.; Mohan, S. K. *Tetrahedron* **1999**, *55*, 11331. (d) Manabe, S. *Chem. Commun.* **1997**, 737. (e) David, K.; Ariento, C.; Greiner, A.; Goré, J.; Cazes, B. *Tetrahedron Lett.* **1996**, *37*, 3335. (f) Wolff, S.; Agosta, W. C. *Can. J. Chem.* **1984**, *62*, 2429. (g) Biollaz, M.; Haefliger, W.; Velarde, E.; Crabbe, P.; Fried, J. H. *J. Chem. Soc. D* **1971**, *0*, 1322.